United Therapeutics (UTHR) Tops Q3 EPS by 85c, Beats on Revenue
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $497.97 +2.12%
Revenue Growth %: -1.2%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $4.91, $0.85 better than the analyst estimate of $4.06. Revenue for the quarter came in at $516 million versus the consensus estimate of $493.81 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- Chime to acquire Stride Bank for $590M in cash
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
